Mary Scholand, MD
Pulmonary Disease · Salt Lake City, UTNPI 1639269251
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by United Therapeutics Corporation at 50.2% of the total. 2025 is the largest year on record at $94,490, 6.2 times the $15,290 reported in 2019. Among pulmonary disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $920.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$163K
- Boehringer Ingelheim$101K
- Daiichi Sankyo Inc.$36K
- Genentech USA, Inc.$6K
- Roche Products Limited$6K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $8K from 5 others
Across 446 payments — averaging $6228.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$813K
- United Therapeutics Corporation$762K
- Roche Products Limited$591K
- E.r. Squibb & Sons, L.L.C.$192K
- Novartis$124K
- Bristol Myers Squibb$70K
- plus $225K from 10 others
What the payments were for
- Consulting fees$147,12345%
- Speaking & faculty fees$138,26543%
- Grants$3,0001%
- Travel & lodging$26,2838%
- Food & beverage$10,1113%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 188 | $163,174 |
| Boehringer Ingelheim | 87 | $100,959 |
| Daiichi Sankyo Inc. | 34 | $35,891 |
| Genentech USA, Inc. | 10 | $6,155 |
| Roche Products Limited | 4 | $6,000 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,308 |
| Genentech, Inc. | 6 | $3,436 |
| AbbVie | 2 | $3,018 |
| Merck | 11 | $1,413 |
| Insmed, Inc. | 7 | $473 |
| Sandoz | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$324,861 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 297 | $3,760,087 |
| Pirfenidone | 263 | $346,133 |
| Fasenra PenBenralizumab | 14 | $70,735 |
| EsbrietPirfenidone | 13 | $16,101 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,558 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $9,721 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,641 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,538 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,960 |
| Mycophenolate Mofetil | 90 | $8,405 |
| Mycophenolic AcidMycophenolate Sodium | 20 | $7,170 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,792 |
| Advair DiskusFluticasone Propion/Salmeterol | 17 | $4,541 |
| DuleraMometasone/Formoterol | 11 | $3,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $100,959 | $3,769,728315 claims |
| Genentech USA, Inc.Esbriet | $6,155 | $16,10113 claims |
| MerckDulera | $1,413 | $3,74811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Salt Lake City
- Chakravarthy ReddySalt Lake City$82K
- James PearlSalt Lake City$69K
- Jefferson ChambersSalt Lake City$57K
- Lara HardmanSalt Lake City$37K
- Charles ElliottSalt Lake City$12K
- Jacqueline ChoaSalt Lake City$9K
- Ann JefferdsSalt Lake City$9K
- Erin BlackstockSalt Lake City$7K
- Michael BourneSalt Lake City$6K
- Kurt FrancisSalt Lake City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.